We use cookies to understand how you use our site and to improve your experience.
This includes personalizing content and advertising.
By pressing "Accept All" or closing out of this banner, you consent to the use of all cookies and similar technologies and the sharing of information they collect with third parties.
You can reject marketing cookies by pressing "Deny Optional," but we still use essential, performance, and functional cookies.
In addition, whether you "Accept All," Deny Optional," click the X or otherwise continue to use the site, you accept our Privacy Policy and Terms of Service, revised from time to time.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
SYK Q3 Earnings Call Highlights Softer Demand and Revised Outlook
Read MoreHide Full Article
Key Takeaways
Stryker lowers 2026 organic sales growth guidance to 6.5%-7% and adjusted EPS outlook to $14.80-$14.90.
SYK faces slower hip and knee procedures, supply constraints and commercial disruptions affecting execution.
MedSurg and Neurotechnology sales grew 9.1%, while operating margin rose 60 basis points to 26.2%.
Stryker Corporation (SYK - Free Report) lowered its 2026 outlook after third-quarter performance fell short of management's expectations, reflecting weaker hip and knee procedures, peripheral vascular supply disruptions and commercial execution challenges.
During the earnings call, executives discussed slowing joint replacement demand, corrective actions and a strong medical technology pipeline. Management also emphasized continued capital equipment demand, margin expansion and opportunities in surgical robotics heading into 2027.
Third-quarter adjusted earnings per share of $3.52 missed the Zacks Consensus Estimate of $3.56. Revenues of $6.52 billion missed the Zacks Consensus Estimate of $6.57 billion by 0.90%.
Stryker Corporation Price, Consensus and EPS Surprise
Stryker revised its full-year organic sales growth guidance to 6.5%-7% and adjusted earnings per share guidance to $14.80-$14.90.
Chairman and CEO Kevin Lobo attributed the revision to weaker joint replacement procedures and operational distractions. CFO Preston Wells indicated that fourth-quarter organic growth should remain broadly comparable to the third quarter.
Stryker Faces Slower Hip and Knee Demand
Lobo identified affordability pressures, higher insurance deductibles and increased preauthorization denials as factors delaying joint replacement procedures.
During the Q&A, a JPMorgan analyst questioned the extent of the slowdown. Lobo estimated annual hip and knee market growth at approximately 2.5%, below historical levels.
Management also acknowledged weaker competitive conversion activity. The earlier cybersecurity incident and July SAP implementation disrupted commercial execution, particularly for Mako RPS and Triathlon Gold.
SYK Highlights Strength in Medical Technology
MedSurg and Neurotechnology delivered 9.1% organic growth, supported by Endoscopy, Medical and capital equipment demand.
Wells reported 13% U.S. organic Endoscopy growth, reflecting operating room infrastructure investment and Sports Medicine strength. U.S. Medical sales advanced 10%, supported by Sage and Smart Care.
Orthopaedics organic sales increased 5.9%, with Ortho Tech benefiting from strong Mako installations and orthopedic power tools. Management expects Trauma and Extremities to deliver stronger growth in the fourth quarter.
Third-quarter sales benefited from a one-time regulatory milestone payment associated with the company's China joint venture. Management expects inventory availability to normalize through year-end.
During the Q&A, a Piper Sandler analyst questioned the recovery trajectory. Lobo highlighted the planned commercialization of AVS' intravascular lithotripsy platform in 2027 and anticipated PEERLESS II clinical data as future growth opportunities.
SYK Expands Robotics and Innovation Investments
Stryker announced a strategic investment in CMR Surgical alongside an agreement to become the exclusive U.S. sales agent for its Versius robotic platform.
Responding to a Wells Fargo analyst, Lobo described the investment structure as a way to limit financial and development exposure while establishing a U.S. commercial presence. He indicated that Stryker ultimately intends to acquire the business.
Management also highlighted upcoming product introductions, including Neptune, Sonopet 3, System 10 and the 1888 endoscopy platform. A powered hip impaction solution is planned for 2027 to strengthen competitive positioning.
Stryker Maintains Margin and Capital Discipline
Adjusted operating margin increased 60 basis points to 26.2%, supported by operational efficiencies and expense management.
Wells emphasized that margin improvements helped offset the earnings impact of weaker sales. During the Q&A, management reaffirmed its commitment to further manufacturing efficiencies despite unfavorable Orthopaedics sales mix.
Stryker repurchased $1 billion of shares during the quarter and received an additional $3 billion repurchase authorization. Wells reiterated that strategic acquisitions remain the primary capital allocation priority.
SYK Focuses on Execution Ahead of Leadership Transition
Lobo expressed confidence in Stryker's diversified portfolio and innovation pipeline while acknowledging uncertainty surrounding joint replacement recovery.
The company's priorities include improving commercial execution, restoring supply availability and maintaining strong capital equipment demand. Incoming CEO Spencer Stiles will inherit these objectives as Stryker prepares its 2027 operating plans.
Zacks Rank and Style Scores Reflect Caution
SYK currently carries a Zacks Rank #4 (Sell), reflecting an unfavorable near-term earnings estimate revision outlook. Its Value Score of D indicates relatively weak valuation characteristics, while its Growth Score of B reflects more favorable growth attributes. You can see the complete list of today’s Zacks #1 Rank (Strong Buy) stocks here.
The stock's Momentum Score of C and VGM Score of C indicate neutral characteristics in these categories. Although its Growth Score is favorable, the Zacks Rank #4 remains a cautionary signal under the Zacks framework. The rank can change as analysts revise earnings estimates following the third-quarter results.
View the Zacks #1 Rank List
Image: Bigstock
SYK Q3 Earnings Call Highlights Softer Demand and Revised Outlook
Key Takeaways
Stryker Corporation (SYK - Free Report) lowered its 2026 outlook after third-quarter performance fell short of management's expectations, reflecting weaker hip and knee procedures, peripheral vascular supply disruptions and commercial execution challenges.
During the earnings call, executives discussed slowing joint replacement demand, corrective actions and a strong medical technology pipeline. Management also emphasized continued capital equipment demand, margin expansion and opportunities in surgical robotics heading into 2027.
Third-quarter adjusted earnings per share of $3.52 missed the Zacks Consensus Estimate of $3.56. Revenues of $6.52 billion missed the Zacks Consensus Estimate of $6.57 billion by 0.90%.
Stryker Corporation Price, Consensus and EPS Surprise
Stryker Corporation price-consensus-eps-surprise-chart | Stryker Corporation Quote
SYK Cuts 2026 Outlook Amid Procedure Weakness
Stryker revised its full-year organic sales growth guidance to 6.5%-7% and adjusted earnings per share guidance to $14.80-$14.90.
Chairman and CEO Kevin Lobo attributed the revision to weaker joint replacement procedures and operational distractions. CFO Preston Wells indicated that fourth-quarter organic growth should remain broadly comparable to the third quarter.
Stryker Faces Slower Hip and Knee Demand
Lobo identified affordability pressures, higher insurance deductibles and increased preauthorization denials as factors delaying joint replacement procedures.
During the Q&A, a JPMorgan analyst questioned the extent of the slowdown. Lobo estimated annual hip and knee market growth at approximately 2.5%, below historical levels.
Management also acknowledged weaker competitive conversion activity. The earlier cybersecurity incident and July SAP implementation disrupted commercial execution, particularly for Mako RPS and Triathlon Gold.
SYK Highlights Strength in Medical Technology
MedSurg and Neurotechnology delivered 9.1% organic growth, supported by Endoscopy, Medical and capital equipment demand.
Wells reported 13% U.S. organic Endoscopy growth, reflecting operating room infrastructure investment and Sports Medicine strength. U.S. Medical sales advanced 10%, supported by Sage and Smart Care.
Orthopaedics organic sales increased 5.9%, with Ortho Tech benefiting from strong Mako installations and orthopedic power tools. Management expects Trauma and Extremities to deliver stronger growth in the fourth quarter.
Stryker Addresses Peripheral Vascular Disruptions
Lobo reported progress restoring Peripheral Vascular product availability after manufacturing-related supply constraints affected performance.
Third-quarter sales benefited from a one-time regulatory milestone payment associated with the company's China joint venture. Management expects inventory availability to normalize through year-end.
During the Q&A, a Piper Sandler analyst questioned the recovery trajectory. Lobo highlighted the planned commercialization of AVS' intravascular lithotripsy platform in 2027 and anticipated PEERLESS II clinical data as future growth opportunities.
SYK Expands Robotics and Innovation Investments
Stryker announced a strategic investment in CMR Surgical alongside an agreement to become the exclusive U.S. sales agent for its Versius robotic platform.
Responding to a Wells Fargo analyst, Lobo described the investment structure as a way to limit financial and development exposure while establishing a U.S. commercial presence. He indicated that Stryker ultimately intends to acquire the business.
Management also highlighted upcoming product introductions, including Neptune, Sonopet 3, System 10 and the 1888 endoscopy platform. A powered hip impaction solution is planned for 2027 to strengthen competitive positioning.
Stryker Maintains Margin and Capital Discipline
Adjusted operating margin increased 60 basis points to 26.2%, supported by operational efficiencies and expense management.
Wells emphasized that margin improvements helped offset the earnings impact of weaker sales. During the Q&A, management reaffirmed its commitment to further manufacturing efficiencies despite unfavorable Orthopaedics sales mix.
Stryker repurchased $1 billion of shares during the quarter and received an additional $3 billion repurchase authorization. Wells reiterated that strategic acquisitions remain the primary capital allocation priority.
SYK Focuses on Execution Ahead of Leadership Transition
Lobo expressed confidence in Stryker's diversified portfolio and innovation pipeline while acknowledging uncertainty surrounding joint replacement recovery.
The company's priorities include improving commercial execution, restoring supply availability and maintaining strong capital equipment demand. Incoming CEO Spencer Stiles will inherit these objectives as Stryker prepares its 2027 operating plans.
Zacks Rank and Style Scores Reflect Caution
SYK currently carries a Zacks Rank #4 (Sell), reflecting an unfavorable near-term earnings estimate revision outlook. Its Value Score of D indicates relatively weak valuation characteristics, while its Growth Score of B reflects more favorable growth attributes. You can see the complete list of today’s Zacks #1 Rank (Strong Buy) stocks here.
The stock's Momentum Score of C and VGM Score of C indicate neutral characteristics in these categories. Although its Growth Score is favorable, the Zacks Rank #4 remains a cautionary signal under the Zacks framework. The rank can change as analysts revise earnings estimates following the third-quarter results.